---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-22-024145"
form_type: "8-K"
ticker: "AURA"
cik: "0001501796"
company_name: "Aura Biosciences, Inc."
filed_at: "2022-11-10T23:59:59+00:00"
generated_at: "2026-06-21T22:48:31.664495+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Aura Biosciences reports Q3 2022 net loss of $15.9M; initiates global Phase 3 trial for bel-sar in choroidal melanoma

## Summary
- Net loss $15.9M for Q3 2022 vs $8.8M YoY; cash $111.5M sufficient into 2024.
- Research & development expenses $11.3M (+77% YoY); G&A $4.8M (+92% YoY).
- Global Phase 3 trial for bel-sar in early-stage choroidal melanoma initiated: 3-arm, masked, ~75 patients, adaptive design.
- Positive Phase 2 interim data: tumor growth rate reduction (p=0.0007), 88.9% tumor control rate, favorable safety.
- First patient dosed in Phase 1 for NMIBC; initial data expected in 2023.

## SEC filing metadata
- accession: 0000950170-22-024145
- form_type: 8-K
- ticker: AURA
- cik: 0001501796
- company_name: Aura Biosciences, Inc.
- filed_at: 2022-11-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1501796/000095017022024145/0000950170-22-024145-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1501796/000095017022024145/aura-20221110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-22-024145
- JSON: https://secwatch.observer/filing/0000950170-22-024145.json
- Plain text: https://secwatch.observer/filing/0000950170-22-024145.txt

## Key facts
- Earnings Releases
  Aura Biosciences, Inc. reported financial results for the quarter ended September 30, 2022.
  - Period: the quarter ended September 30, 2022
  - Result: reported results
  source text: On November 10, 2022, Aura Biosciences Inc, (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1501796/000095017022024145/0000950170-22-024145-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.